Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

October 10, 2015


Company: TEVA Pharmaceuticals Ireland.
Legal category: Prescription. GMS. Sport Permitted.
Active ingredient: Alfuzosin hydrochloride10mg.
Description: White, round, bevelled-edges, prolonged releasetablet.
Presentation: 30, €18.78.
Indications: Moderate to severe functional symptoms of benignprostatic hyperplasia (BPH).

Pharmacology: Alfuzosin is an orally acting quinazolin derivative,which selectively blocks post-synaptic alpha-1-receptors and thus relaxessmooth muscle and improves urinary flow.
Dosage: Adult: 10mg daily, taken as immediately after the same meal each day. Tablet should be swallowed whole with a sufficient amount of fluid (e.g. a glass of water) and initial dose taken at bedtime. Elderly: As per adults. Children: Not recommended.
Contraindications: Hypersensitivity to alfuzosin, other quinazolines (e.g. terazosin, doxazosin) or to any of the excipients. Conditions with orthostatic hypotension. Hepatic insufficiency. Severe renal impairment (cc<30ml/min); not recommended (nodata).
Special precautions: Transient postural hypotension may develop within a few hours of administration; lie down until the symptoms have totally disappeared (inform patient). Caution: Patients who developed pronounced hypotension with other alpha-1-blockers, acute cardiac failure. Hypersensitivity to other alpha-1-blockers, initiate treatment gradually. If angina pectoris recurs or worsens, discontinue. The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery (inform surgeon of current or past treatment).Contains lactose.
Drug interactions: Not recommended: Other alpha-1-receptor blocking agents, potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycine, erythromycine). Caution: Antihypertensive agents (monitor BP), nitrates. Anaesthetics, withdraw tablets 24 hours previously.
Adverse drug reactions: Dizziness, headache, vertigo, malaise, postural hypotension, nausea, GI disorders, asthenia.
Full prescribing information and references available from TEVA Pharmaceuticals Ireland. Telephone: 1800 201700.